ACRO BIOMEDICAL CO., LTD.

2022 Q3 Form 10-Q Financial Statement

#000164033422001752 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.19K $12.11K $357.7K
YoY Change -89.53% -94.38% 1368.27%
Cash & Equivalents $16.19K $12.11K $357.7K
Short-Term Investments
Other Short-Term Assets $16.74K $20.30K $23.85K
YoY Change -19.9% -16.8% -14.52%
Inventory $296.0K $296.0K
Prepaid Expenses $4.740K $8.295K $11.85K
Receivables $278.5K $298.5K $298.5K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $607.4K $626.9K $680.0K
YoY Change -2.59% -8.87% -26.11%
LONG-TERM ASSETS
Property, Plant & Equipment $31.99K $38.20K $44.35K
YoY Change 410.21% 206.34% 138.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.230K $4.230K $4.230K
YoY Change
Total Long-Term Assets $36.22K $42.43K $48.58K
YoY Change 477.86% 240.14% 160.91%
TOTAL ASSETS
Total Short-Term Assets $607.4K $626.9K $680.0K
Total Long-Term Assets $36.22K $42.43K $48.58K
Total Assets $643.6K $669.3K $728.6K
YoY Change 2.19% -4.43% -22.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.90K $15.00K $0.00
YoY Change 30.06% 24.28% -100.0%
Accrued Expenses $25.46K $25.21K $24.96K
YoY Change 332.26% 107.49% 35.95%
Deferred Revenue
YoY Change
Short-Term Debt $78.59K $21.25K $21.03K
YoY Change 299.95% 33.4% -91.84%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $145.0K $81.46K $65.99K
YoY Change 135.28% 35.4% -78.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.530K $12.99K $19.39K
YoY Change
Total Long-Term Liabilities $6.530K $12.99K $19.39K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $145.0K $81.46K $65.99K
Total Long-Term Liabilities $6.530K $12.99K $19.39K
Total Liabilities $151.5K $94.44K $85.38K
YoY Change 145.88% 56.99% -72.46%
SHAREHOLDERS EQUITY
Retained Earnings -$19.87M -$15.86M -$11.87M
YoY Change 386.65% 1351.45% 3879.66%
Common Stock $60.04K $60.04K $60.04K
YoY Change -99.81% -99.7% -93.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $492.2K $574.9K $643.2K
YoY Change
Total Liabilities & Shareholders Equity $643.6K $669.3K $728.6K
YoY Change 2.19% -4.43% -22.4%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001622996
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60042000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60042000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60042000 shares
us-gaap Earnings Per Share Potentially Dilutive Securities
EarningsPerSharePotentiallyDilutiveSecurities
0
us-gaap Earnings Per Share Potentially Dilutive Securities
EarningsPerSharePotentiallyDilutiveSecurities
0
us-gaap Operating Lease Expense
OperatingLeaseExpense
13140 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
12571 usd
CY2021Q4 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
4230 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55643
dei Entity Registrant Name
EntityRegistrantName
ACRO BIOMEDICAL CO., LTD.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1950356
dei Entity Address Address Line1
EntityAddressAddressLine1
12175 Visionary Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1160
dei Entity Address City Or Town
EntityAddressCityOrTown
Fishers
dei Entity Address State Or Province
EntityAddressStateOrProvince
IN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
46038
dei City Area Code
CityAreaCode
317
dei Local Phone Number
LocalPhoneNumber
286-6788
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60042000 shares
CY2022Q2 us-gaap Cash
Cash
12107 usd
CY2021Q4 us-gaap Cash
Cash
95248 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
298500 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
598000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
296000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
0 usd
CY2022Q2 acro Purchase Deposit For Inventory Current
PurchaseDepositForInventoryCurrent
12000 usd
CY2021Q4 acro Purchase Deposit For Inventory Current
PurchaseDepositForInventoryCurrent
12000 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8295 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1167 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
626902 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
706415 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38199 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50432 usd
CY2022Q2 us-gaap Security Deposit
SecurityDeposit
4230 usd
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
4230 usd
CY2022Q2 us-gaap Assets
Assets
669331 usd
CY2021Q4 us-gaap Assets
Assets
761077 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
26197 usd
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20000 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
21245 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
20741 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25211 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24713 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
81456 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
91651 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12988 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25719 usd
CY2022Q2 us-gaap Liabilities
Liabilities
94444 usd
CY2021Q4 us-gaap Liabilities
Liabilities
117370 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60042000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
60042 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
60042 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32293950 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32293530 usd
CY2022Q2 acro Deferred Stock Compensation Equity
DeferredStockCompensationEquity
-15917183 usd
CY2021Q4 acro Deferred Stock Compensation Equity
DeferredStockCompensationEquity
-23773383 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15861922 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7936482 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
574887 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
643707 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
669331 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
761077 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
500000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
298500 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
599500 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
420000 usd
us-gaap Cost Of Revenue
CostOfRevenue
222000 usd
us-gaap Cost Of Revenue
CostOfRevenue
490000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2021Q2 us-gaap Gross Profit
GrossProfit
80000 usd
us-gaap Gross Profit
GrossProfit
76500 usd
us-gaap Gross Profit
GrossProfit
109500 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1476432 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
231595 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2961520 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
318086 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2520000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
641725 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5040000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
641725 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3996432 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
873320 usd
us-gaap Operating Expenses
OperatingExpenses
8001520 usd
us-gaap Operating Expenses
OperatingExpenses
959811 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3996432 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-793320 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7925020 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-850311 usd
CY2022Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
211 usd
CY2021Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1367 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
420 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
3870 usd
CY2022Q2 us-gaap Other Expenses
OtherExpenses
211 usd
CY2021Q2 us-gaap Other Expenses
OtherExpenses
1367 usd
us-gaap Other Expenses
OtherExpenses
420 usd
us-gaap Other Expenses
OtherExpenses
3870 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3996643 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-794687 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7925440 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-854181 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-7925440 usd
us-gaap Net Income Loss
NetIncomeLoss
-854181 usd
CY2022Q2 acro Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.07
CY2021Q2 acro Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.02
acro Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.13
acro Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.02
CY2022Q2 acro Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
60042000 shares
CY2021Q2 acro Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
50515077 shares
acro Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
60042000 shares
acro Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
49145149 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
643707 usd
CY2022Q1 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
3928100 usd
CY2022Q1 acro Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
209 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3928797 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
643219 usd
CY2022Q2 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
3928100 usd
CY2022Q2 acro Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
211 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3996643 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
574887 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
685868 usd
CY2021Q1 acro Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
2503 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-59494 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
628877 usd
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
804650 usd
CY2021Q2 acro Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
1367 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-794687 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
640207 usd
us-gaap Net Income Loss
NetIncomeLoss
-7925440 usd
us-gaap Net Income Loss
NetIncomeLoss
-854181 usd
acro Imputed Interest Related Parties
ImputedInterestRelatedParties
-420 usd
acro Imputed Interest Related Parties
ImputedInterestRelatedParties
-3870 usd
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
7856200 usd
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
804650 usd
acro Change Of Rou And Lease Liabilities
ChangeOfRouAndLeaseLiabilities
0 usd
acro Change Of Rou And Lease Liabilities
ChangeOfRouAndLeaseLiabilities
120 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-299500 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
296000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-490000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7128 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7167 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11197 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-12662 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83645 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
424390 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
504 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
14832 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
241851 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
504 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-227019 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-83141 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
197371 usd
CY2021Q4 us-gaap Cash
Cash
95248 usd
CY2020Q4 us-gaap Cash
Cash
18123 usd
CY2022Q2 us-gaap Cash
Cash
12107 usd
CY2021Q2 us-gaap Cash
Cash
215494 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p>
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
504 usd
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
14832 usd
CY2022Q2 us-gaap Due To Officers Or Stockholders Current And Noncurrent
DueToOfficersOrStockholdersCurrentAndNoncurrent
20145 usd
CY2021Q4 us-gaap Due To Officers Or Stockholders Current And Noncurrent
DueToOfficersOrStockholdersCurrentAndNoncurrent
19641 usd
us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.05 pure
us-gaap Receivable With Imputed Interest Effective Yield Interest Rate
ReceivableWithImputedInterestEffectiveYieldInterestRate
0.04 pure
us-gaap Interest Income Related Party
InterestIncomeRelatedParty
420 usd
us-gaap Interest Income Related Party
InterestIncomeRelatedParty
3870 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38199 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50432 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25211 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24713 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12988 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25719 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
38199 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
50432 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
13140 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
26280 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
39420 usd
CY2022Q2 acro Restricted Stock Grants Issued
RestrictedStockGrantsIssued
370000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7856200 usd
us-gaap Share Based Compensation
ShareBasedCompensation
804650 usd
CY2022Q2 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
15917183 usd
CY2021Q4 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
23773383 usd

Files In Submission

Name View Source Status
0001640334-22-001752-index-headers.html Edgar Link pending
0001640334-22-001752-index.html Edgar Link pending
0001640334-22-001752.txt Edgar Link pending
0001640334-22-001752-xbrl.zip Edgar Link pending
acro-20220630.xsd Edgar Link pending
acro_10q.htm Edgar Link pending
acro_ex311.htm Edgar Link pending
acro_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
acro-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acro-20220630_def.xml Edgar Link unprocessable
acro_10q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acro-20220630_cal.xml Edgar Link unprocessable
acro-20220630_pre.xml Edgar Link unprocessable